Focus on HIV Care

SORT BY:     Most Recent      Most Viewed
  • September 1, 2006
    PREVIEW

    The highlighted topics at the XVI International AIDS Conference held in Toronto in August 2006 included prevention, future treatment alternatives, and the possibility of pre-exposure prophylaxis...

  • August 1, 2006
    PREVIEW

    Highly active antiretroviral therapy (HAART)—three or more antiretrovirals including either a protease inhibitor (PI) or nonnucleoside reductase inhibitor (NNRTI)—increased systolic or diastolic...

  • April 1, 2006
    PREVIEW

    Antiretroviral regimens are complicated and subject to a host of influences, and to increase the likelihood of achieving therapeutic responses, researchers are studying both pharmacogenetics and...

  • April 1, 2006
    PREVIEW

    A study in Neurology suggests that HIV-infected patients who have been exposed to stavudine (Zerit—Bristol-Myers Squibb) or didanosine have significantly heightened risks for developing...

  • February 1, 2006
    PREVIEW

    Some medications used in highly active antiretroviral therapy (HAART) have been to varying degrees associated with hepatotoxicity and diabetes. Another area of current concern in HIV therapy is...

Pages